Lung Cancer

December 28, 2015December 28, 2015

Afatinib Appears To Be Better First-Line Option For EGFR-mutated Lung Cancer

Lung Cancer, News

According to clinical results recently presented at the ESMO Asia 2015 Congress in Singapore, patients with EGFR-activating mutations in advanced lung cancer have more clinical benefits from being treated with ... Read more

December 21, 2015December 21, 2015

Lung Cancer Genetically Distinct, More Aggressive in Younger Patients, Study Finds

Lung Cancer, News

Scientists at Dana-Farber Cancer Institute in Boston found non-small cell lung cancer (NSCLC) — the most common type of lung cancer and one that can metastasize to other parts of the body — is ... Read more

December 17, 2015December 17, 2015

PD-L1 Protein Expression Needs Further Assays to Become a Biomarker for NSCLC

Lung Cancer, News

Researchers found that because expression levels of PD-L1 protein vary in patients’ tumors from non–small cell lung cancer (NSCLC), additional studies are required to develop predictive biomarkers for NSCLC. The ... Read more

December 16, 2015December 16, 2015

E-Cigarette Flavorings Linked to Likely Respiratory Disease-causing Chemicals

Lung Cancer, News

Researchers found flavoring chemicals like diacetyl, previously reported to be associated with severe respiratory disease, in the juices used in e-cigarettes. The study, entitled “Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 ... Read more

December 15, 2015May 12, 2016

NSCLC Trial of Treatment for Patients with Squamous Histology Advances

Lung Cancer, News

BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing a targeted and programmable therapeutics called ACCURINS, has announced that the Phase 2 iNSITE1 clinical trial of its lead drug candidate, BIND-014, is ready to move to ... Read more

December 14, 2015December 14, 2015

FDA Approves Genentech’s ALECENSA as Oral Therapy for Advanced ALK-positive Non-small Cell Lung Cancer

Lung Cancer, News

ALECENSA (alectinib), a therapy commercialized by Genentech, was approved by U.S. Food and Drug Administration for the treatment of patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) previously ... Read more

November 25, 2015November 30, 2015

Eli Lilly Therapy for Metastatic Squamous NSCLC Gets FDA Approval

Lung Cancer, News

A novel treatment for a particularly deadly form of lung cancer has just been approved by the U.S. Food and Drug Administration (FDA) — Eli Lilly and Company‘s Portrazza (necitumumab) a monoclonal ... Read more

November 25, 2015November 25, 2015

AstraZeneca’s Treatment for Advanced NSCLC Is Approved by FDA

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for AstraZeneca’s Tagrisso (osimertinib), an oral prescription for the treatment of patients with advanced non-small cell lung cancer (NSCLC). The drug is ... Read more

November 24, 2015November 25, 2015

Immune Evasion by Lung Cancer Tumors Linked to Problems in a Gene

Lung Cancer, News

Recent research offers new insights into the role of a gene called “p53” in lung cancer, connecting this gene to an immune system defense against tumor growth. The paper, entitled “PDL1 Regulation ... Read more

November 20, 2015November 20, 2015

Blood Test Finding Lung Cancer in Patients in Ongoing Study

Lung Cancer, News

VolitionRx Limited recently announced initial data showing a high level of accuracy and specificity in the use of its NuQ® blood tests in the detection of lung cancer. Lung cancer is characterized by ... Read more